Biogen Net Worth

Biogen Net Worth Breakdown

The net worth of Biogen Inc is the difference between its total assets and liabilities. Biogen's net worth represents the value of the company's equity or ownership interest. In other words, it is the amount of money that would be left over if all of Biogen's assets were sold and all of its debts were paid off. Net worth is sometimes referred to as shareholder's equity or book value. Biogen's net worth can be used as a measure of its financial health and stability which can help investors to decide if Biogen is a good investment. It is also essential in determining the company's creditworthiness and ability to secure financing before investing in Biogen Inc stock.

Biogen Net Worth Analysis

Biogen's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Biogen's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Biogen's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Biogen's net worth analysis. One common approach is to calculate Biogen's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Biogen's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Biogen's net worth. This approach calculates the present value of Biogen's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Biogen's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Biogen's net worth. This involves comparing Biogen's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Biogen's net worth relative to its peers.

Enterprise Value

4.21 Billion

To determine if Biogen is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Biogen's net worth research are outlined below:
Biogen Inc has a poor financial position based on the latest SEC disclosures
Over 93.0% of the company shares are held by institutions such as insurance companies
Latest headline from Investors who lost money on Biogen Inc. should contact Levi Korsinsky about pending Class Action - BIIB

Biogen Quarterly Good Will

6.23 Billion

Biogen uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Biogen Inc. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Biogen's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
13th of February 2024
Upcoming Quarterly Report
23rd of April 2024
Next Financial Report
31st of December 2023
Next Fiscal Quarter End
13th of February 2024
Next Fiscal Year End
30th of September 2023
Last Quarter Report
31st of December 2022
Last Financial Announcement

Know Biogen's Top Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Biogen is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Biogen Inc backward and forwards among themselves. Biogen's institutional investor refers to the entity that pools money to purchase Biogen's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
T. Rowe Price Associates, Inc.2024-03-31
1.6 M
Beutel, Goodman & Company Ltd.2024-03-31
1.6 M
Clearbridge Advisors, Llc2024-03-31
1.6 M
Legal & General Group Plc2024-03-31
1.6 M
Norges Bank2023-12-31
1.5 M
Northern Trust Corp2024-03-31
1.4 M
Bank Of New York Mellon Corp2024-03-31
1.4 M
Dimensional Fund Advisors, Inc.2024-03-31
1.3 M
Deutsche Bank Ag2024-03-31
1.1 M
Vanguard Group Inc2024-03-31
16.6 M
Primecap Management Company2024-03-31
16.2 M
Note, although Biogen's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Follow Biogen's market capitalization trends

The company currently falls under 'Large-Cap' category with a current market capitalization of 32.96 B.

Market Cap

4.18 Billion

Project Biogen's profitablity

Last ReportedProjected for Next Year
Return On Tangible Assets 0.09  0.08 
Return On Capital Employed 0.06  0.08 
Return On Assets 0.04  0.06 
Return On Equity 0.08  0.10 
The company has Profit Margin (PM) of 0.12 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.27 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.27.
When accessing Biogen's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Biogen's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Biogen's profitability and make more informed investment decisions.
The data published in Biogen's official financial statements typically reflect Biogen's business processes, product offerings, services, and other fundamental events. However, there are additional fundamental indicators that are easier to understand and visualize along the underlying realities that are driving Biogen's quantitative information. For example, before you start analyzing numbers published by Biogen accountants, it's essential to understand Biogen's liquidity, profitability, and earnings quality within the context of the Biotechnology space in which it operates.
Please note, the presentation of Biogen's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Biogen's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Biogen's management manipulating its earnings.

Evaluate Biogen's management efficiency

Biogen Inc has return on total asset (ROA) of 0.0486 % which means that it generated a profit of $0.0486 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0805 %, meaning that it created $0.0805 on every $100 dollars invested by stockholders. Biogen's management efficiency ratios could be used to measure how well Biogen manages its routine affairs as well as how well it operates its assets and liabilities. At present, Biogen's Return On Capital Employed is projected to increase slightly based on the last few years of reporting. The current year's Return On Assets is expected to grow to 0.06, whereas Return On Tangible Assets are forecasted to decline to 0.08. At present, Biogen's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 21 B, whereas Non Currrent Assets Other are forecasted to decline to about 270.1 M.
Last ReportedProjected for Next Year
Book Value Per Share 102.28  107.39 
Tangible Book Value Per Share 1.50  1.43 
Enterprise Value Over EBITDA 16.83  17.67 
Price Book Value Ratio 2.53  2.40 
Enterprise Value Multiple 16.83  17.67 
Price Fair Value 2.53  2.40 
Enterprise Value6.4 B4.2 B
The analysis of Biogen's management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Biogen's future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Biogen Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Enterprise Value Revenue
9.7 B
Quarterly Revenue Growth
Revenue Per Share
Return On Equity
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Biogen insiders, such as employees or executives, is commonly permitted as long as it does not rely on Biogen's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Biogen insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Biogen Corporate Filings

25th of June 2024
Report filed with the SEC to announce major events that shareholders should know about
20th of June 2024
Other Reports
3rd of May 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
26th of April 2024
Other Reports
Biogen time-series forecasting models is one of many Biogen's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Biogen's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Biogen Earnings per Share Projection vs Actual

Biogen Corporate Executives

Elected by the shareholders, the Biogen's board of directors comprises two types of representatives: Biogen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Biogen. The board's role is to monitor Biogen's management team and ensure that shareholders' interests are well served. Biogen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Biogen's outside directors are responsible for providing unbiased perspectives on the board's policies.
Michael CPAExecutive CFOProfile

Additional Information and Resources on Investing in Biogen Stock

When determining whether Biogen Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biogen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biogen Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biogen Inc Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biogen Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biogen. If investors know Biogen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biogen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
Earnings Share
Revenue Per Share
Quarterly Revenue Growth
Return On Assets
The market value of Biogen Inc is measured differently than its book value, which is the value of Biogen that is recorded on the company's balance sheet. Investors also form their own opinion of Biogen's value that differs from its market value or its book value, called intrinsic value, which is Biogen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biogen's market value can be influenced by many factors that don't directly affect Biogen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biogen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biogen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biogen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.